FASN and type 2 diabetes mellitus: Xie et al. reveals that elevated METTL3 expression in Type 2 diabetes (T2D) patients inhibits hepatic insulin sensitivity via N6-methylation of Fasn (fatty acid synthase) mRNA, and subsequently promotes fatty acid metabolism 97.